Rapid NoteThe vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes
Section snippets
Acknowledgements
This study was supported by Research Concerted Actions of the Communauté Française de Belgique.
References (15)
- et al.
Peptides
(1994) - et al.
J. Neuroimmunol.
(1994) - et al.
Regul. Pept.
(1993) - et al.
Peptides
(1997) - et al.
J. Neuroimmunol.
(1996) - et al.
Science
(1970) - et al.
J. Immunol.
(1986)
Cited by (49)
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses
2015, Brain, Behavior, and ImmunityCitation Excerpt :Nonetheless, a specific although mild immunomodulatory role of VPAC2 has been demonstrated in different in vitro and in vivo experimental models. For example, the VPAC2 agonist Ro25-1553 significantly decreased the production of TNFα and IL-12 by LPS-stimulated peritoneal macrophages and human monocytes in vitro (Delgado et al., 2000; Dewit et al., 1998), and was partially beneficial in mouse LPS-induced endotoxemia (Delgado et al., 2000). These studies were performed by administering receptor analogs for a short period of time.
VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis
2011, Cellular ImmunologyCitation Excerpt :This was further highlighted by reduced transcript levels of IL-6, IL-1β and MMP-9 in VPAC2-KO mice treated with PKA inhibitors (Fig. 5). VIP and VIP analogs have been proposed as therapeutic agents for multiple autoimmune diseases because they have major inhibitory effects on T cell and macrophage proliferation and cytokine secretion [16,23–25]. Earlier investigations by Gomariz and colleagues showed that VIP is important for normal regulation of intestinal immune pathways.
Vasoactive intestinal peptide: An anti-inflammatory neuropeptide
2007, Psychoneuroimmunology, Two-Volume SetSignaling mechanisms of vasoactive intestinal peptide in inflammatory conditions
2006, Regulatory PeptidesVasoactive Intestinal Peptide: An Anti-Inflammatory Neuropeptide
2006, PsychoneuroimmunologyVIP- and PACAP-mediated immunomodulation as prospective therapeutic tools
2003, Trends in Molecular Medicine